Drug intelligence / Profile preview

FPE016

Development stage: Unknown
Lead developer: Guangdong Fapon Biopharma
Modality: Small Molecules

Overview

FPE016 is a drug initially developed by Guangdong Fapon Biopharma Inc. It functions as a modulator of Interleukin-10 (IL-10) and Vascular endothelial growth factor receptor 2 (VEGFR2). The drug is currently in the discovery phase of development and is being investigated for its potential therapeutic applications in neoplasms.

Targets

IL10 (Interleukin-10)VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on FPE016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPE016.

Explore the full profile